BSE Pharma Sector Regulatory Filings — May 13, 2026

13-05-2026

GlaxoSmithKline Pharmaceuticals Limited reported consolidated FY26 revenue from operations of ₹382167 Lakhs, up 2% YoY from ₹374921 Lakhs, though Q4 FY26 revenue declined 4% QoQ to ₹99530 Lakhs from ₹104126 Lakhs. Net profit for FY26 rose 12% YoY to ₹103598 Lakhs from ₹92758 Lakhs, aided by ₹2062 Lakhs exceptional items credit, while Q4 profit grew 6% YoY to ₹27786 Lakhs. The Board recommended a final dividend of Rs.57 per equity share (face value Rs.10) subject to approval at the 101st AGM on June 30, 2026, with record date May 29, 2026.

• · Record date for dividend: Friday, May 29, 2026.
• · 101st AGM date: Tuesday, June 30, 2026 via Video Conferencing/Other Audio Visual Means.
• · Dividend payment on/after July 1, 2026 if approved.
• · Company confirms non-applicability as Large Corporate: no debt securities, no long-term borrowings > Rs. 1,000 Crores, no credit ratings.
• · Exceptional items FY26: Rs.264 lakhs (surplus residential properties) + Rs.1798 lakhs (non-operational land).
• · Labour Codes impact: Rs.1182 lakhs increase in employee benefits expense FY26.
• · Total equity FY26: ₹226742 Lakhs (up from ₹195131 Lakhs FY25).
• · Paid-up equity share capital: 16941 Lakhs (face value Rs.10).

13-05-2026

GlaxoSmithKline Pharmaceuticals Limited reported consolidated revenue from operations of ₹382167 L for FY26, up 1.9% YoY from ₹374921 L but nearly flat, while profit for the year rose 11.7% to ₹103598 L supported by exceptional items credit of ₹2062 L. Total expenses declined to ₹258164 L from ₹263995 L, though Q4 revenue grew modestly 2.2% to ₹99530 L from ₹97437 L. The Board recommended a final dividend of Rs.57/- per equity share (face value Rs.10), fixed record date as May 29, 2026, and scheduled the 101st AGM for June 30, 2026.

• · Record date for dividend: Friday, 29th May 2026
• · 101st AGM date: Tuesday, 30th June 2026 via VC/AVM
• · Dividend payment on/after Wednesday, 1st July 2026
• · Company not classified as Large Corporate (no debt securities, borrowings < Rs. 1,000 Crores, no credit ratings)
• · Labour Codes impact: incremental ₹1182 L increase in employee benefits expense FY26
• · Exceptional items FY26: ₹264 L (surplus residential properties) + ₹1798 L (non-operational land)
• · Consolidated total assets: ₹432387 L (31.03.2026) vs ₹410808 L (31.03.2025)

13-05-2026

GlaxoSmithKline Pharmaceuticals Limited reported FY26 standalone revenue of ₹3790cr (+2% YoY) and Q4 FY26 revenue of ₹989cr (+2% YoY), with EBITDA margins expanding to 34.3% (+290 bps) and PAT reaching ₹1010cr (+11% YoY), driven by gross margin improvements, cost efficiencies, and growth in innovative portfolio including oncology and adult vaccines. However, revenue growth was muted due to supply constraints in pharma sales and vaccines shipment phasing, while some categories like Advanced Oral Antibiotics declined -2% and key brands showed mixed efficiency indices with Eltroxin at 94. The company sustained competitive performance in representative markets growing 7.3% (vs acute market 8.9%) and advanced pipeline with 26 ongoing clinical trials.

• · Gross margin FY26 at 64.8%
• · ROCE FY26 at 61%
• · Final dividend Rs.57 per share
• · EPS FY26 excluding exceptionals 59.6 (+10%)
• · Innovation portfolio 6% of Q4 sales
• · FUV share expanded to 12% post-LOE

13-05-2026

GlaxoSmithKline Pharmaceuticals Limited disclosed the outcome of scheduled Analyst/Institutional Investor Meetings on May 13, 2026, pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The audio and video recording has been uploaded to the company's investor relations page at https://india-pharma.gsk.com/en-in/investors/analyst-meets/. No specific financial or operational details were provided in the filing.

• · Filing reference: CIN L24239MH1924PLC001151
• · Contact details: GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030; Tel: +91 22 2495 9595; Email: askus@gsk.com

13-05-2026

Zydus Lifesciences Limited, through its subsidiary Zydus Worldwide DMCC and Zara Merger Sub Inc., has signed a definitive agreement to acquire all outstanding shares of U.S.-based Assertio Holdings, Inc. (NASDAQ: ASRT) for USD 23.50 per share in cash, totaling approximately USD 166.4 million on a fully-diluted basis. The deal provides an immediate U.S. specialty oncology commercial footprint anchored by Assertio's ROLVEDON® product, which reported adjusted turnover growth from USD 60.09 million in CY2024 to USD 68.23 million in CY2025 (13.6% YoY), following an asset sale; the transaction is structured as a tender offer followed by merger, expected to close in FY2026-27 subject to customary conditions and approvals.

• · Assertio headquartered in Lake Forest, Illinois; focused on specialty oncology supportive-care therapies.
• · Transaction subject to customary closing conditions including tender of majority shares and regulatory approvals; tender offer to commence within five business days.
• · Assertio to be delisted from Nasdaq post-merger; approved by boards of Zydus Worldwide and Assertio.
• · Assertio sold non-surviving assets on April 8, 2026 to Cottage Pharmaceuticals Inc.

13-05-2026

Zydus Lifesciences Limited announced that its Q4 FY26 (January-March 2026) financial results will be declared on May 19, 2026. A post-results Q&A session via webinar is scheduled for the same day at 4:00 p.m. IST, hosted by Dr. Sharvil Patel, Managing Director. Participants are required to pre-register using the provided link, with audio recording and transcript to be available on the company's InvestorZone website.

• · Pre-registration link for earnings call: https://bit.ly/4wo3Oyj
• · Q4 FY26 Earnings Presentation to be available on Company’s InvestorZone post results announcement
• · Pursuant to SEBI LODR Regulation 30(6) read with Part A of Schedule III

13-05-2026

Cipla's FY26 consolidated revenue from operations grew 2.23% YoY to ₹28,162.59 Cr, driven by product sales, however Q4 revenue declined 2.80% YoY to ₹6,541.20 Cr and annual profit before exceptional items fell 19.35% to ₹5,499.54 Cr, impacted by an exceptional loss of ₹275.91 Cr leading to net profit dropping 26.71% YoY to ₹3,861.74 Cr. Balance sheet strengthened with total assets up 13.60% to ₹42,495.98 Cr and cash & equivalents rising to ₹1,018.22 Cr, though operating cash flow decreased 21.30% to ₹3,940.02 Cr. The board recommended a final dividend of INR 13 per equity share (face value ₹2), with record date of 5th June 2026.

• · Auditor’s report with unmodified opinion on audited financial results.
• · Impairment of investment in associates: ₹42.02 Cr.
• · Declaration from Global Chief Financial Officer confirming unmodified opinion.
• · Board meeting commenced 09:45 a.m. IST on 13th May 2026, still in progress at filing.
• · EPS basic FY26: ₹48.03 (vs ₹65.29 FY25); Diluted: ₹48.00 (vs ₹65.24).

13-05-2026

Cipla's consolidated revenue from operations for FY26 grew modestly 2.2% YoY to ₹28,162.59 Cr, driven by product sales, however Q4 FY26 revenue declined 2.8% YoY to ₹6,541.20 Cr and sequentially from ₹7,074.48 Cr in Q3. Net profit for FY26 fell sharply 26.7% YoY to ₹3,861.74 Cr, impacted by a ₹275.91 Cr exceptional loss and ₹42.02 Cr impairment, with Q4 profit down 55% YoY to ₹542.51 Cr; the Board recommended a final dividend of ₹13 per equity share (record date June 5, 2026). Total assets expanded to ₹42,495.98 Cr from ₹37,387.04 Cr.

• · EPS basic FY26: ₹48.03 (vs ₹65.29 FY25)
• · Record date for dividend: June 5, 2026
• · Board meeting commenced May 13, 2026 at 09:45 a.m. IST
• · Ongoing NPPA demands; ₹175.08 Cr deposited per SC order

13-05-2026

Cipla's consolidated revenue from operations grew 2.3% YoY to ₹28,162.59 Cr for FY26 ended 31st March 2026, driven by product sales, however profit before tax declined 23.4% to ₹5,223.63 Cr due to an exceptional loss of ₹275.91 Cr and higher expenses. Q4 FY26 revenue fell 2.8% YoY to ₹6,541.20 Cr with net profit dropping 55.3% to ₹542.51 Cr, while net profit for the year decreased 26.7% to ₹3,861.74 Cr. The Board recommended a final dividend of INR 13 per equity share (face value ₹2), subject to shareholder approval, with record date 5th June 2026.

• · Auditor’s report with unmodified opinion on audited financial results.
• · Declaration from Global Chief Financial Officer confirming unmodified opinion.
• · Paid-up equity share capital: ₹161.56 Cr (face value ₹2 each).
• · Record date for final dividend: 5th June 2026.
• · Ongoing NPPA litigation with ₹175.08 Cr deposited per Supreme Court order.
• · Board meeting commenced 09:45 a.m. IST on 13th May 2026, still in progress at filing.

13-05-2026

Cipla Limited's Board approved the 90th Annual General Meeting on June 25, 2026, granted 25,323 stock options under ESOS 2013-A and 747,310 ESARs under ESAR 2021 (across various vesting periods), all at an exercise price of INR 2. The Board also appointed M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27 and Mr. Sushrut Kulkarni as President & Global Chief – Integrated Product Development, effective May 18, 2026. These measures support employee incentives, audit compliance, and leadership strengthening with no adverse developments noted.

• · Board meeting held on May 13, 2026, commencing at 9:45 a.m. IST and concluding at 1:00 p.m. IST.
• · M/s Joshi Apte & Associates (Firm Registration no. 000240) appointed as Cost Auditors for FY 2026-27.
• · Details disclosed per SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and SEBI Listing Regulations with Master Circular dated January 30, 2026.

13-05-2026

GlaxoSmithKline Pharmaceuticals Limited reported consolidated revenue from operations of 382167 Lakhs for FY26, up 2% YoY from 374921 Lakhs (flat growth), while profit after tax surged 12% to 103598 Lakhs driven by exceptional gains of 2062 Lakhs and lower expenses. Q4 FY26 revenue declined 4% QoQ from 104126 Lakhs but grew 2% YoY to 99530 Lakhs, with PAT down 6% QoQ to 27786 Lakhs. The board recommended a final dividend of Rs.57 per equity share (face value Rs.10), up from total Rs.54 last year, subject to approval at the 101st AGM on 30 June 2026.

• · Record date for dividend: 29 May 2026
• · 101st AGM date: 30 June 2026 via Video Conferencing/Other Audio Visual Means
• · Dividend payment on/after 1 July 2026 if approved
• · Company not classified as Large Corporate (no debt securities, no borrowings > Rs.1,000 Cr, no credit ratings)
• · Only one reportable segment: Pharmaceuticals
• · Unmodified audit opinion on FY26 results
• · Cash generated from operations FY26: 90330 Lakhs (down from 128991 Lakhs FY25)

13-05-2026

GlaxoSmithKline Pharmaceuticals Limited reported consolidated revenue from operations of ₹382167 L for FY26, up 1.93% YoY from ₹374921 L, driven by modest Q4 growth of 2.15% YoY to ₹99530 L, while profit after tax rose 11.66% YoY to ₹103598 L supported by exceptional gains of ₹2062 L and lower expenses. The board recommended a final dividend of Rs.57 per equity share (up from total Rs.54 last year) subject to approval at the June 30, 2026 AGM, with record date May 29, 2026. However, Q4 revenue declined 4.4% QoQ from ₹104126 L, total expenses remained relatively flat YoY, and net cash from operations fell 30% YoY to ₹90330 L.

• · Record date for dividend: Friday, May 29, 2026.
• · 101st AGM date: Tuesday, June 30, 2026 via Video Conferencing/Other Audio Visual Means.
• · Company confirms non-applicability as Large Corporate (no debt securities, no borrowings > Rs. 1,000 Crore, no credit ratings).
• · Exceptional items FY26: Rs.264 L (profit on sale of surplus residential properties) + Rs.1798 L (sale of non-operational land).
• · Total assets grew to ₹432387 L from ₹410808 L YoY.
• · Cash and cash equivalents surged to ₹110205 L from ₹53885 L.